- Home
- FTHM vs ITRM Comparison
FTHM vs ITRM Comparison
Compare FTHM & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- ITRM
- Stock Information
- Founded
- FTHM 2010
- ITRM 2015
- Country
- FTHM United States
- ITRM Ireland
- Employees
- FTHM N/A
- ITRM N/A
- Industry
- FTHM Real Estate
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- ITRM Health Care
- Exchange
- FTHM Nasdaq
- ITRM Nasdaq
- Market Cap
- FTHM 38.3M
- ITRM 40.0M
- IPO Year
- FTHM 2020
- ITRM 2018
- Fundamental
- Price
- FTHM $2.82
- ITRM $0.68
- Analyst Decision
- FTHM
- ITRM Strong Buy
- Analyst Count
- FTHM 0
- ITRM 2
- Target Price
- FTHM N/A
- ITRM $7.00
- AVG Volume (30 Days)
- FTHM 1.5M
- ITRM 749.8K
- Earning Date
- FTHM 11-06-2025
- ITRM 11-13-2025
- Dividend Yield
- FTHM N/A
- ITRM N/A
- EPS Growth
- FTHM N/A
- ITRM N/A
- EPS
- FTHM N/A
- ITRM N/A
- Revenue
- FTHM $390,032,000.00
- ITRM N/A
- Revenue This Year
- FTHM $25.22
- ITRM N/A
- Revenue Next Year
- FTHM $16.19
- ITRM $249.35
- P/E Ratio
- FTHM N/A
- ITRM N/A
- Revenue Growth
- FTHM 19.16
- ITRM N/A
- 52 Week Low
- FTHM $0.65
- ITRM $0.61
- 52 Week High
- FTHM $3.37
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- FTHM 70.20
- ITRM 43.17
- Support Level
- FTHM $1.80
- ITRM $0.61
- Resistance Level
- FTHM $2.98
- ITRM $0.76
- Average True Range (ATR)
- FTHM 0.45
- ITRM 0.05
- MACD
- FTHM 0.09
- ITRM 0.01
- Stochastic Oscillator
- FTHM 83.44
- ITRM 49.65
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.